New combo aims to outsmart resistant stomach cancers
NCT ID NCT05274048
First seen Nov 01, 2025 · Last updated May 05, 2026 · Updated 30 times
Summary
This early-phase trial tests a combination of two targeted drugs, neratinib and fam-trastuzumab deruxtecan (Enhertu), in people with advanced stomach, esophageal, or other gastrointestinal cancers that have a specific marker called HER2. Participants must have already tried at least one prior treatment that stopped working. The main goal is to find the safest dose and check for early signs of tumor shrinkage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fox Chase Cancer Center
RECRUITINGPhiladelphia, Pennsylvania, 19111, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Roswell Park Comprehensive Cancer Center
RECRUITINGBuffalo, New York, 14263, United States
Contact Email: •••••@•••••
Contact
-
Stanford Cancer Center
RECRUITINGPalo Alto, California, 94304, United States
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.